A phase II, randomised, double blind placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis

Trial Profile

A phase II, randomised, double blind placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Pulmonary fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 13 Jun 2016 Planned End Date changed from 1 Jan 2017 to 25 Jul 2016.
    • 14 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top